公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2018 | Organ-specific differential responses to immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma | Lu, Li-Chun; Hsu, Chiun; Shao, Yu-Yun; Chao, Yee; Yen, Chia-Jui; Shih, I.-Lun; Hung, Yi-Ping; Chang, Chun-Jung; Shen, Ying-Chun; Guo, Jhe-Cyuan; Liu, Tsung-hao; Hsu, Chih-Hung; Cheng, Ann-Lii; YI-PING HUNG | Cancer Research | | 1 | |
2020 | Role of Eg5 in Prognosis Prediction and Treatment of Hepatocellular Carcinoma | Shao, Yu-Yun; Sun, Nai-Yun; Jeng, Yung-Ming; YAO-MING WU ; Hsu, Chiun; Hsu, Chih-Hung | ResearchSquare | | 0 | |
2012 | Transforming growth factor-beta mediated epithelial to mesenchymal transition contributes to in vivo resistance to sorafenib in hepatocellular carcinoma | Lin, Shiou-Der; Lin, Tzu-Hsuan; Feng, Wen-Chi; Shao, Yu-Yun; Cheng, Ann-Lii; Hsu, Chih-Hung | Cancer Res. | 0 | 0 | |
2013 | WNT/beta-catenin signaling inhibitors improve the anti-proliferative effect of sorafenib against hepatocellular carcinoma (HCC) cells. | Lin, Hsiao-Hui; Feng, Wen-Chi; Lu, Li-Chun; Shao, Yu-Yun; Cheng, Ann-Lii; Hsu, Chih-Hung; 鄭安理 | Cancer Res. | | | |
2013 | WNT/beta-catenin signaling inhibitors improve the anti-proliferative effect of sorafenib against hepatocellular carcinoma (HCC) cells. | Lin, Hsiao-Hui; Feng, Wen-Chi; Lu, Li-Chun; Shao, Yu-Yun; Cheng, Ann-Lii; Hsu, Chih-Hung | Cancer Res. | | | |